がん遺伝子治療の市場規模、シェア、動向分析レポート：治療別、最終用途別、地域別、セグメント予測、2024年～2030年

がん遺伝子治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のがん遺伝子治療市場規模は2030年までに127億6,000万米ドルに達する見込みです。

同市場は、世界の新規治療薬に対する需要の増加と世界のがん罹患率の上昇により、2024年から2030年にかけてCAGR 18.9％を記録すると予測されています。さらに、この治療法はさまざまな種類の遺伝性がんや誘発がんに対する絶対的な解決策を提供するため、がん治療薬としてより望ましい選択肢となっています。例えば、Kite社のTecartus（brexucabtagene autoleucel）は、再発または難治性のB細胞前駆体急性リンパ芽球性白血病の治療薬としてFDAに承認されています。

世界中で悪性腫瘍の有病率が増加しており、効果的な治療と悪性腫瘍の発生率の増加に対抗するための様々な戦略の必要性が推進されると予想されます。さらに、市場における技術の進歩は、新規治療薬に新たな機会を提供すると期待されています。その結果、製品の承認数が増加しています。例えば、2022年3月、欧州医療機関はCarvykti（ciltacabtagene autoleucel）を再発難治性多発性骨髄腫の治療に使用する条件付き販売承認を推奨しました。

同市場は、世界中の政府および各国のがん学会からの有利な支援によって積極的に牽引されています。がん遺伝子治療の研究資金を増やすことにますます注目が集まっています。例えば、2021年12月、DARE-NL（オランダ）と呼ばれるオランダのプラットフォームは、KWFオランダがん協会から520万米ドルの助成金を獲得しました。この助成金により、DARE-NLは、恵まれない人々が利用できる細胞・遺伝子治療戦略をレベルアップすることができます。

アジアのメーカーは、大量生産が可能な複雑でない分子に重点を置いているため、新しく複雑な技術への投資は比較的少ないです。そのため、欧州や北米など他の先進地域のメーカーにとっては、競争圧力を回避するために、高収量・低コスト技術への投資が選択肢となっています。

市場で事業を展開する主な企業は、強力ながん遺伝子治療薬の開発のための共同研究に注力しています。例えば、2022年8月、Gensaic社はOvid Therapeutics社と、独自のファージ由来粒子遺伝子治療プラットフォームを用いた中枢神経系を適応症とする最大3種類の遺伝子医薬品の開発に関する共同研究契約を締結しました。

がん遺伝子治療市場レポートハイライト

• 遺伝子レベルでのがん病態の解明が進み、遺伝子誘導免疫療法や個別化医療へのニーズが高まる中、市場は重要な転換期を迎えています。
• 遺伝子誘導免疫療法研究の進展により、遺伝子誘導免疫療法分野が2023年に最大シェアを占めました。
• バイオ製薬企業は、新規遺伝子治療に対する需要の高まりとがん遺伝子治療のFDA承認件数の増加により、2023年に最大の市場シェアを占めました。バイオ製薬企業は、この分野における研究開発活動の増加により、予測期間中に最も急成長すると予測されています。
• 北米は、主要プレイヤーの存在と、同地域のがん研究を推進するための政府および国立がん研究所からの支援増加により、2023年の市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 がん遺伝子治療市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場 促進要因分析
  • 市場抑制要因分析
• がん遺伝子治療市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 がん遺伝子治療市場：治療別推定・動向分析

• セグメントダッシュボード
• がん遺伝子治療市場：治療別変動分析
• がん遺伝子治療市場：治療別展望
• 2018年から2030年までの市場規模と予測および動向分析
• 腫瘍溶解性ウイルス療法
• 遺伝子誘導免疫療法
• 遺伝子導入

第5章 がん遺伝子治療市場：最終用途別推定・動向分析

• セグメントダッシュボード
• がん遺伝子治療市場：最終用途変動分析
• がん遺伝子治療市場：最終用途別展望
• 2018年から2030年までの市場規模と予測および動向分析
• 建設機関
• バイオ医薬品企業
• 診断センター
• その他

第6章 がん遺伝子治療市場：治療法と最終用途別の地域別推定・動向分析

• 地域ダッシュボード
• がん遺伝子治療市場：地域別変動分析
• がん遺伝子治療市場：技術と最終用途別の地域推定・動向分析
• 2018年から2030年までの市場規模と予測および動向分析
• 北米
• 欧州
• アジア太平洋
• その他の国

第7章 競合情勢

• 市場参入企業の分類
• 主要企業プロファイル
  • Abeona Therapeutics Inc.
  • Asklepios BioPharmaceutical Inc.
  • Altor Bioscience Inc.
  • Bluebird bio Inc.
  • BioCancell Inc.
  • CelgeneInc.
  • Elevate BioInc.
  • GlaxoSmithKlineInc.
  • Genelux Corporation
  • GenVec
  • Introgen TherapeuticsInc.
  • OncoGenex Pharmaceuticals Inc.

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
• Table 4 Global cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
• Table 5 North America cancer gene therapy market, by region, 2018 - 2030 (USD Million)
• Table 6 North America cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
• Table 7 North America cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
• Table 8 U.S. cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
• Table 9 U.S. cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
• Table 10 Canada cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
• Table 11 Canada cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
• Table 12 Mexico cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
• Table 13 Mexico cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
• Table 14 Europe cancer gene therapy market, by country, 2018 - 2030 (USD Million)
• Table 15 Europe cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
• Table 16 Europe cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
• Table 17 UK cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
• Table 18 UK cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
• Table 19 Germany cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
• Table 20 Germany cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
• Table 21 Switzerland cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
• Table 22 Switzerland cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
• Table 23 Asia Pacific cancer gene therapy market, by country, 2018 - 2030 (USD Million)
• Table 24 Asia Pacific cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
• Table 25 Asia Pacific cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
• Table 26 Japan cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
• Table 27 Japan cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
• Table 28 China cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
• Table 29 China cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
• Table 30 Australia cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
• Table 31 Australia cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
• Table 32 Rest of World cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
• Table 33 Rest of World cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Information Procurement Primary Research Pattern
• Fig. 2 Market Research Approaches
• Fig. 3 Value Chain-Based Sizing & Forecasting
• Fig. 4 Market Formulation & Validation
• Fig. 5 Market driver analysis
• Fig. 6 Market restraint analysis
• Fig. 7 PESTEL Analysis
• Fig. 8 Porter's Five Forces Analysis
• Fig. 9 Cancer gene therapy market, therapy outlook key takeaways (USD Million)
• Fig. 10 Cancer gene therapy market: Therapy movement analysis 2023 & 2030 (USD Million)
• Fig. 11 Oncolytic Virotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 12 Gene induced immunotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 13 Gene transfer market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 14 Cancer gene therapy market, end use outlook key takeaways (USD Million)
• Fig. 15 Cancer gene therapy market: End use movement analysis (USD Million), 2023 & 2030
• Fig. 16 Research institutes market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 17 Biopharmaceutical companies market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 18 Diagnostic centers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 19 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Cancer gene therapy market: Regional key takeaways (USD Million)
• Fig. 21 Cancer gene therapy market: regional outlook, 2023 & 2030 (USD Million)
• Fig. 22 North America cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 U.S. cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Canada cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Mexico cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Europe cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 UK cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Germany cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Switzerland cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Asia Pacific cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 China cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Japan cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Australia cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Rest of World cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)

Cancer Gene Therapy Market Growth & Trends:

The global cancer gene therapy market size is expected to reach USD 12.76 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 18.9% from 2024 to 2030 owing to the increasing demand for novel therapeutics globally and rising incidence of cancer cases globally. Moreover, this therapy offers an absolute solution to different kinds of inherited and induced cancer conditions, which makes it a more desired option for cancer therapeutics. For instance, Kite's Tecartus (brexucabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

There is an increasing prevalence of malignant tumor cases across the globe, which is expected to propel the need for various strategies for effective treatment and to combat the increasing incidence of malignant tumors. Moreover, technological advancements in the market are expected to provide new opportunities for novel therapeutics. As a result, there is an increasing number of product approvals. For instance, in March 2022, European Medicine Agency recommended conditional marketing authorization for Carvykti (ciltacabtagene autoleucel) to be used for the treatment of subjects with relapsed and refractory multiple myeloma.

The market is positively driven by the lucrative support from the government and national cancer societies across the globe. There has been an increasing focus on increasing funds for research on cancer gene therapy. For instance, in December 2021, The Dutch platform called DARE-NL (in the Netherlands) has been awarded a USD 5.2 million grant from the KWF Dutch cancer society. The grant allows the DARE-NL to level up the availability of cell and gene therapy strategies accessible to the needy population.

The investment in new and complex technologies is relatively low for Asian manufacturers as they are more focused on less complex molecules that can be produced in bulk. Thus, the investment in high-yielding, low-cost technologies is an alternative for manufacturers in other developed regions such as Europe and North America to avoid competitive pressure.

Key players operating in the market are focusing on collaborations for the development of potent cancer gene therapy drugs. For instance, in August 2022, Gensaic signed a collaboration with Ovid Therapeutics for the development of up to three genetic medicines for central nervous system indications using its proprietary phage-derived particle gene therapy platform.

Cancer Gene Therapy Market Report Highlights:

• The market is witnessing a key shift with the rise in gene level understanding of a cancer condition and rising need for gene induced immunotherapy and personalized medicine
• The gene induced immunotherapy segment held the largest share in 2023 due to increase in the advancement in gene induced immunotherapy research
• Biopharmaceutical companies held the largest market share in 2023 owing to rising demand for novel gene therapy and increasing number of FDA approvals for cancer gene therapy. Biopharmaceutical companies are anticipated to witness the fastest growth in the forecast period due to increasing research and development activities in the field
• North America dominated the market in 2023 due to the presence of key players and rising support from the government and National Cancer Institute to advance the research on oncology in the region.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapy
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Cancer Gane Therapy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. High growth of the pharmaceutical industry
    • 3.2.1.2. Rising R&D investments and demand for novel cancer therapeutics
    • 3.2.1.3. Increased incidence of cancers
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High product prices
    • 3.2.2.2. Unethical use of gene therapy
• 3.3. Cancer Gene Therapy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cancer Gane Therapy Market: Therapy Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Cancer Gene Therapy Market: Therapy Movement Analysis
• 4.3. Cancer Gene Therapy Market by Therapy Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Oncolytic Virotherapy
  • 4.5.1. Oncolytic Virotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Gene Induced Immunotherapy
  • 4.6.1. Gene Induced Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Gene Transfer
  • 4.7.1. Gene Transfer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Gene Therapy Market: End Use Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Cancer Gene Therapy Market: End Use Movement Analysis
• 5.3. Cancer Gene Therapy Market by End Use Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Research Institutes
  • 5.5.1. Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Biopharmaceutical Companies
  • 5.6.1. Biopharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Diagnostic Centers
  • 5.7.1. Diagnostic Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Therapy and End Use

• 6.1. Regional Dashboard
• 6.2. Regional Cancer Gene Therapy Market Movement Analysis
• 6.3. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Technology & End Use
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. North America
  • 6.5.1. North America Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. U.S.
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement scenario
    • 6.5.2.5. U.S. Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Canada
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement scenario
    • 6.5.3.5. Canada Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement scenario
    • 6.5.4.5. Canada Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. Europe Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. UK
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement scenario
    • 6.6.2.5. UK Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. Germany
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement scenario
    • 6.6.3.5. Germany Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. Switzerland
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement scenario
    • 6.6.4.5. Switzerland Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Japan
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement scenario
    • 6.7.2.5. Japan Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. China
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement scenario
    • 6.7.3.5. China Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. Reimbursement scenario
    • 6.7.4.5. Australia Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Rest of World
  • 6.8.1. Latin America Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Key Company Profiles
  • 7.2.1. Abeona Therapeutics Inc.
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. Asklepios BioPharmaceutical Inc.
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Altor Bioscience Inc.
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Bluebird bio Inc.
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. BioCancell Inc.
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. CelgeneInc.
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Elevate BioInc.
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. GlaxoSmithKlineInc.
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. Genelux Corporation
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. GenVec
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. Introgen TherapeuticsInc.
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. OncoGenex Pharmaceuticals Inc.
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives